On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
What do the next 100 years have in store for healthcare and clinical research? Biorasi's Few & Far Between podcast welcomes Professor Bertil E....
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...
On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, talks with Will Maier, VP of Rare Disease, Drug Development...